Diana Hausman - Zymeworks Common Chief Medical Officer
| ZYME Stock | USD 13.10 0.04 0.31% |
Executive
Dr. Diana Hausman, M.D. is Chief Medical Officer of the Company. She is a board certified medical oncologist and brings more than 15 years of clinical drug development experience to our management team. Prior to joining Zymeworks Inc. in June 2016, she was Chief Medical Officer at Oncothyreon Inc. from 2012 to 2016, where she oversaw the clinical program for their lead Phase 2 targeted antiHER2 cancer therapy. While there, Dr. Hausman also led planning for the clinical development of a therapeutic vaccine, and earlier served as the companys vice president of clinical development from 2009 to 2011. She has also held positions at ZymoGenetics, Inc., Berlex, Inc. and Immunex Corporation working across multiple indications, including oncology, hematology, hepatitis C and autoimmune disease. Dr. Hausman received her internal medicine training and specialty training in hematology and medical oncology at the University of Washington. She holds an M.D. degree from the University of Pennsylvania and an A.B. in biology from Princeton University. since 2016.
| Age | 51 |
| Tenure | 8 years |
| Address | 108 Patriot Drive, Middletown, DE, United States, 19709 |
| Phone | 302 274 8744 |
| Web | https://www.zymeworks.com |
Latest Insider Transactions
Zymeworks Common Management Efficiency
The company has return on total asset (ROA) of (0.1469) % which means that it has lost $0.1469 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2873) %, meaning that it created substantial loss on money invested by shareholders. Zymeworks Common's management efficiency ratios could be used to measure how well Zymeworks Common manages its routine affairs as well as how well it operates its assets and liabilities. As of December 11, 2024, Return On Tangible Assets is expected to decline to -0.23. In addition to that, Return On Capital Employed is expected to decline to -0.28. At present, Zymeworks Common's Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's Intangibles To Total Assets is expected to grow to 0.12, whereas Non Currrent Assets Other are forecasted to decline to about 5.3 M.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Adam Townsend | Apellis Pharmaceuticals | 47 | |
| Michael MBA | Annexon | 53 | |
| PharmD Rasbach | Zentalis Pharmaceuticals Llc | 44 | |
| Andrew Callos | Cytokinetics | 55 | |
| Angela Giannantonio | Travere Therapeutics | N/A | |
| Debra Sieminski | Terns Pharmaceuticals | N/A | |
| Gary MD | Alector | 62 | |
| Carena Spivey | Protagonist Therapeutics | N/A | |
| Marc Damelin | Mersana Therapeutics | N/A | |
| Caren Deardorf | Editas Medicine | 59 | |
| Kathryn Haviland | Blueprint Medicines Corp | 48 | |
| Mark Delong | Apellis Pharmaceuticals | 47 | |
| John Stubenrauch | Day One Biopharmaceuticals | N/A | |
| FACNP FACP | Y mAbs Therapeutics | 76 | |
| Brian JD | Relay Therapeutics | 50 | |
| William Rote | Travere Therapeutics | 61 | |
| Naomi Eichenbaum | Travere Therapeutics | N/A | |
| Susan Smith | Y mAbs Therapeutics | 53 | |
| Scott Harris | Terns Pharmaceuticals | N/A | |
| Qing Yuan | Cabaletta Bio | 53 | |
| Mr MD | Bluebird bio | 58 | |
Management Performance
| Return On Equity | -0.29 | ||||
| Return On Asset | -0.15 |
Zymeworks Common Stock Leadership Team
Elected by the shareholders, the Zymeworks Common's board of directors comprises two types of representatives: Zymeworks Common inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Zymeworks. The board's role is to monitor Zymeworks Common's management team and ensure that shareholders' interests are well served. Zymeworks Common's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Zymeworks Common's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Jack Spinks, Associate Relations | ||
| Neil MD, Chief Officer | ||
| Mark Hollywood, Executive Operations | ||
| Neil Josephson, Interim Chief Medical Officer | ||
| Anthony Polverino, Executive Vice President - Early Development, Chief Scientific Officer | ||
| Christopher Astle, Chief Financial Officer, Senior Vice President | ||
| Thomas Kreudenstein, Director Engineering | ||
| Paul Moore, Chief Officer | ||
| Diana Papove, Senior Communications | ||
| Jeffrey MD, Executive Officer | ||
| Diana Hausman, Chief Medical Officer | ||
| Nina Weisser, Director Therapeutics | ||
| Kenneth Galbraith, Chairman of the Board, President, Chief Executive Officer | ||
| Leone MBA, EVP CFO | ||
| Ryan Dercho, Senior Affairs | ||
| Lota Zoth, Lead Independent Director | ||
| Kenneth CA, CEO Chairman | ||
| Daniel JD, Corporate VP | ||
| Lindsey BSc, Vice Development | ||
| Shrinal Inamdar, Director Relations | ||
| Ali Tehrani, President, Chief Executive Officer, Co-Founder, Director | ||
| Neil Klompas, Chief Financial Officer, Executive Vice President - Business Operations | ||
| Josemund MBBS, Managing Pacific | ||
| Laura OConnor, Head Resources | ||
| John Fann, Senior Sciences | ||
| David Poon, VP Management |
Zymeworks Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Zymeworks Common a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.29 | ||||
| Return On Asset | -0.15 | ||||
| Profit Margin | (1.83) % | ||||
| Operating Margin | (2.14) % | ||||
| Current Valuation | 704.55 M | ||||
| Shares Outstanding | 68.88 M | ||||
| Shares Owned By Insiders | 0.08 % | ||||
| Shares Owned By Institutions | 99.92 % | ||||
| Number Of Shares Shorted | 4.21 M | ||||
| Price To Earning | (2.36) X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Zymeworks Common Stock is a strong investment it is important to analyze Zymeworks Common's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Zymeworks Common's future performance. For an informed investment choice regarding Zymeworks Stock, refer to the following important reports:Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Zymeworks Common Stock. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. You can also try the AI Portfolio Architect module to use AI to generate optimal portfolios and find profitable investment opportunities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Zymeworks Common. If investors know Zymeworks will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Zymeworks Common listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.49) | Revenue Per Share 0.831 | Quarterly Revenue Growth (0.03) | Return On Assets (0.15) | Return On Equity (0.29) |
The market value of Zymeworks Common Stock is measured differently than its book value, which is the value of Zymeworks that is recorded on the company's balance sheet. Investors also form their own opinion of Zymeworks Common's value that differs from its market value or its book value, called intrinsic value, which is Zymeworks Common's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Zymeworks Common's market value can be influenced by many factors that don't directly affect Zymeworks Common's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Zymeworks Common's value and its price as these two are different measures arrived at by different means. Investors typically determine if Zymeworks Common is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Zymeworks Common's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.